Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Thirty-eight of 295 subjects participating in a randomized, double-blind, placebo-controlled trial of the efficacy of daily administration of atovaquone/proguanil for malaria prevention developed malaria at some time during the 20-week prophylaxis period. These subjects (3 atovaquone/proguanil recipients and 35 placebo recipients) were treated with 4 tablets of atovaquone/proguanil per day for 3 days. Atovaquone/proguanil provided safe, well-tolerated, and effective therapy for uncomplicated malaria in nonimmune Indonesians.

Original publication




Journal article


Clin Infect Dis

Publication Date





e92 - e95


Adolescent, Adult, Aged, Animals, Antimalarials, Atovaquone, Double-Blind Method, Drug Resistance, Drug Therapy, Combination, Female, Humans, Indonesia, Malaria, Falciparum, Malaria, Vivax, Male, Middle Aged, Naphthoquinones, Plasmodium falciparum, Plasmodium vivax, Proguanil, Treatment Outcome